All Stories

  1. Lack of association between unipolar or bipolar depression and serum aquaporin-4 autoantibodies
  2. Regulatory effect of lithium on hippocampal blood‐brain barrier integrity in a rat model of depressive‐like behavior
  3. ADHD as a Risk Factor for Infection With Covid-19
  4. Increased circulatory IL-6 during 8-week fluoxetine treatment is a risk factor for suicidal behaviors in youth
  5. Seminars in Clinical Psychopharmacology
  6. The association of non-suicidal self-injurious and suicidal behaviors with religiosity in hospitalized Jewish adolescents
  7. Personality Traits and Psychotic Proneness Among Chronic Synthetic Cannabinoid Users
  8. Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists
  9. Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson’s disease
  10. Efficaciousness of Low Affinity Compared to High Affinity TSPO Ligands in the Inhibition of Hypoxic Mitochondrial Cellular Damage Induced by Cobalt Chloride in Human Lung H1299 Cells
  11. Differential methylation of imprinting genes and MHC locus in 22q11.2 deletion syndrome-related schizophrenia spectrum disorders
  12. Levels of Proneness to Boredom in Children with Attention-Deficit/Hyperactivity Disorder On and Off Methylphenidate Treatment
  13. Comorbid personality disorders in manic bipolar I disorder patients is associated with increased use of long-acting injectable antipsychotic treatment and higher rates of rehospitalization
  14. Effects of country of origin and wave of immigration on prevalence of schizophrenia among first and second-generation immigrants: A 30-year retrospective study
  15. Poor performance of the ‘child Reading the Mind in the Eyes Test’ correlates with poorer social-emotional functioning in children with attention-deficit/hyperactivity disorder
  16. Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion
  17. The Placebo Response in Adult ADHD as Objectively Assessed by the TOVA Continuous Performance Test
  18. Long-term effects of intracranial islet grafting on cognitive functioning in a rat metabolic model of sporadic Alzheimer's disease-like dementia
  19. Low levels of serum vitamin D in clozapine-treated schizophrenia patients are associated with high levels of the proinflammatory cytokine IL-6
  20. 18-kDa Translocator Protein Ligands Protect H9C2 Cardiomyocytes from Cigarette Smoke-induced Cell Death: In Vitro Study
  21. Complete Sequence of the 22q11.2 Allele in 1,053 Subjects with 22q11.2 Deletion Syndrome Reveals Modifiers of Conotruncal Heart Defects
  22. A history of prolonged childhood sexual abuse is associated with more severe clinical presentation of borderline personality disorder in adolescent female inpatients – A naturalistic study
  23. The role of inhibition capacities in the Iowa gambling test performance in young tattooed women
  24. Association between prenatal exposure to a 1-month period of repeated rocket attacks and neuropsychiatric outcomes up through age 9: a retrospective cohort study
  25. A retrospective case series of electroconvulsive therapy in the management of comorbid depression and anorexia nervosa
  26. Cigarette smoke, saliva, the translocator protein 18 kDa (TSPO), and oral cancer
  27. The contribution of ADHD and attachment difficulties to online pornography use among students
  28. Adherence to antidepressant medications is associated with reduced premature mortality in patients with cancer: A nationwide cohort study
  29. Effects of Cigarette Smoke on TSPO-related Mitochondrial Processes
  30. The effectiveness of high-dose escitalopram in the treatment of patients suffering from schizophrenia with comorbid obsessive-compulsive disorder
  31. Trafficking of Grafted Pancreatic Islets Into the Brain Lateral Ventricles
  32. Inhibitory Effects of the Two Novel TSPO Ligands 2-Cl-MGV-1 and MGV-1 on LPS-induced Microglial Activation
  33. Add-on benzodiazepines for psychosis-induced aggression
  34. High pretreatment cognitive impulsivity predicts response of oppositional symptoms to methylphenidate in patients with attention-deficit hyperactivity disorder/oppositional defiant disorder
  35. Psychiatrists' attitude towards the use of clozapine in the treatment of refractory schizophrenia: A nationwide survey
  36. The complexity of the interaction between binge-eating and attention
  37. Modulatory effects of cannabinoids on brain neurotransmission
  38. Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review
  39. Positive and Negative Effects of Cannabis and Cannabinoids on Health
  40. Predictors of suicidal behaviors during hospitalization among adolescents admitted due to suicidal behaviors: A 10-year retrospective naturalistic study
  41. Equine Assisted Therapy for Patients with Post Traumatic Stress Disorder: A Case Series Study
  42. Apparent lack of practice effects in the Test of Variables of Attention (TOVA) in adult ADHD
  43. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder
  44. Comparing executive functioning and clinical and sociodemographic characteristics of people with schizophrenia who hold a driver’s license to those who do not
  45. The TSPO Ligands 2-Cl-MGV-1, MGV-1, and PK11195 Differentially Suppress the Inflammatory Response of BV-2 Microglial Cell to LPS
  46. Do young women with tattoos have lower self-esteem and body image than their peers without tattoos? A non-verbal repertory grid technique approach
  47. Risk gene-set and pathways in 22q11.2 deletion-related schizophrenia: a genealogical molecular approach
  48. Beneficial Effect of Betahistine, a Structural Analog of Histamine, in Clozapine-Related Sedation
  49. Personality disorder comorbidity and rehospitalization rates in bipolar disorder: A cohort study
  50. Distinct Response Inhibition Patterns in Obsessive Compulsive Disorder Patients and Pathological Gamblers
  51. Very Low-Dose Mirtazapine (7.5 mg) in Treatment of Acute Antipsychotic-Associated Akathisia
  52. The effect of methylphenidate treatment on psychopathic behavior of patients having attention-deficit hyperactivity disorder with and without oppositional defiant disorder
  53. The role of gender in association between inhibition capacities and risky decision making
  54. Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects
  55. Differences in demographic and clinical characteristics between cannabis users and non-drug users: A retrospective study of patients at first hospitalization due to psychotic symptoms
  56. Intracranial Transplantation of Pancreatic Islets Attenuates Cognitive and Peripheral Metabolic Dysfunctions in a Rat Model of Sporadic Alzheimer’s Disease
  57. A DNA Methylation Signature of Addiction in T Cells and Its Reversal With DHEA Intervention
  58. Obsessive-compulsive symptomatology in female adolescent inpatients with restrictive compared with binge-purge eating disorders
  59. An international multicentre prospective audit of elective rectal cancer surgery; operative approach versus outcome, including transanal total mesorectal excision (TaTME)
  60. Association of mechanical bowel preparation with oral antibiotics and anastomotic leak following left sided colorectal resection: an international, multi-centre, prospective audit
  61. Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral of surgery
  62. Safety of primary anastomosis following emergency left sided colorectal resection: an international, multi-centre prospective audit
  63. The impact of conversion on the risk of major complication following laparoscopic colonic surgery: an international, multicentre prospective audit
  64. Retraction Notice to: Nested Inversion Polymorphisms Predispose Chromosome 22q11.2 to Meiotic Rearrangements
  65. The Impact of Prolonged, Selective, Serotonin Reuptake Inhibitor Treatment on Serum Lipid and Glucose Levels in Children and Adolescents: A Preliminary Prospective Study
  66. Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder
  67. Education and employment trajectories from childhood to adulthood in individuals with 22q11.2 deletion syndrome
  68. Characterizing the Placebo Response in Adults With ADHD
  69. Citizen petition: Sexual side effects of SSRIs and SNRIs
  70. Demographic and Clinical Predictors of Hospitalization in Preschoolers With ADHD
  71. Elevated neutrophil to lymphocyte ratio in non-affective psychotic adolescent inpatients: Evidence for early association between inflammation and psychosis
  72. Adjunctive antidepressants in bipolar depression: A cohort study of six- and twelve-months rehospitalization rates
  73. No apparent association between bipolar disorder and cancer in a large epidemiological study of outpatients in a managed care population
  74. Changes in consumption of opioid analgesics in Israel 2009 to 2016: An update focusing on oxycodone and fentanyl formulations
  75. Association between serum levels of glutamate and neurotrophic factors and response to clozapine treatment
  76. An exploratory study of adolescent response to fluoxetine using psychological and biological predictors
  77. Dehydroepiandrosterone and Addiction
  78. The interaction between neurocognitive functioning, subthreshold psychotic symptoms and pharmacotherapy in 22q11.2 deletion syndrome: A longitudinal comparative study
  79. Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits
  80. Possible Age-Related Progression of Attentional Impairment in ADHD and Its Attenuation by Past Diagnosis and Treatment
  81. Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial
  82. Higher adaptive functioning and lower rate of psychotic comorbidity in married versus unmarried individuals with 22q11.2 deletion syndrome
  83. Low adherence to antidepressants is associated with increased mortality in Parkinson disease patients
  84. Negative subthreshold psychotic symptoms distinguish 22q11.2 deletion syndrome from other neurodevelopmental disorders: A two-site study
  85. RETRACTED: Nested Inversion Polymorphisms Predispose Chromosome 22q11.2 to Meiotic Rearrangements
  86. Runs of homozygosity, copy number variation, and risk for depression and suicidal behavior in an Arab Bedouin kindred
  87. 4.45 Clinical Manifestations of 22q11.2 Deletion Syndrome and the Role of Prematurity in the Emergence of Psychosis
  88. The effect of methylphenidate treatment on suspiciousness in children with ADHD alone or comorbid with ODD
  89. In vitro Effects of the Specific Mitochondrial TSPO Ligand Ro5 4864 in Cultured Human Osteoblasts
  90. The Effectiveness of a Knowledge Translation Cognitive-Educational Intervention for Family Members of Persons Coping with Severe Mental Illness
  91. The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder
  92. Intracerebroventricular Streptozotocin Induces Obesity and Dementia in Lewis Rats
  93. inflammatory markers and clinical outcome in treatment resistant schizophrenia inpatients treated with clozapine
  94. Adjunctive antidepressants to mood stabilizers or atypical antipsychotics in bipolar depression and 1-year rehospitalization rates: a cohort study
  95. The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder
  96. BDNF overexpression prevents cognitive deficit elicited by adolescent cannabis exposure and host susceptibility interaction
  97. Ketamine upregulates eNOS expression in human astroglial A172 cells: Possible role in its antidepressive properties
  98. New developments in brain research of internet and gaming disorder
  99. Trans-generation enrichment of clozapine-responsiveness trait in mice using a subchronic hypo-glutamatergic model of schizophrenia:A preliminary study
  100. Serum Ferritin Levels Are Lower in Children With Tic Disorders Compared with Children Without Tics: A Cross-Sectional Study
  101. The Effectiveness and Safety of Antipsychotic and Antidepressant Medications in Individuals with 22q11.2 Deletion Syndrome
  102. Insulin delivery to the brain using intracranial implantation of alginate-encapsulated pancreatic islets
  103. Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans: Evidence from Studies of Adult Users
  104. Association between Elevated C-Reactive Protein and Manic Polarity in Acute Psychiatric Inpatients with Affective Symptomatology
  105. Nonfunctional Redundant Acts Characterize OCD, Even in OCD-Unrelated Tasks: A Demonstration in Questionnaire Completion
  106. A Multimodal Approach For Studying Pathways Leading To Psychosis In 22Q11 Deletion Syndrome
  107. Symptoms Versus Impairment in Adults With ADHD: Intercorrelations of the BRIEF-A, CAARS, and TOVA
  108. Predictors of developing mathematics anxiety among middle-school students: A 2-year prospective study
  109. Antipsychotic adjunctive therapy to mood stabilizers and 1-year rehospitalization rates in bipolar disorder: A cohort study
  110. Continuous Performance Test Is Sensitive to a Single Methylphenidate Challenge in Preschool Children With ADHD
  111. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System–Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder
  112. Neurocognitive profile in psychotic versus nonpsychotic individuals with 22q11.2 deletion syndrome
  113. The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders
  114. Disturbed DISC1 pathway interacts with adolescent cannabis exposure to produce impaired recognition memory restored by BDNF over-expression: a host-environment mouse model of severe mental illness
  115. One-year rehospitalization rates in bipolar disorder manic patients discharged on mood stabilizers versus mood stabilizer combined with antipsychotics
  116. The effect of continuous acetylsalicylic acid treatment on exacerbations of psychotic disorders, a retrospective longitudinal study
  117. Predictors of short-term outcome variables in hospitalised female adolescents with eating disorders
  118. CD44 Deficiency Is Associated with Increased Susceptibility to Stress-Induced Anxiety-like Behavior in Mice
  119. Levels of depression and satisfaction with life as indicators of health services consumption
  120. Suicide, Satisfaction With Life, and Insight Capacity Among Adolescents With Mental Disorders
  121. Association between prematurity and the evolution of psychotic disorders in 22q11.2 deletion syndrome
  122. Fibre tract analysis using diffusion tensor imaging reveals aberrant connectivity in a rat model of depression
  123. Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital
  124. Gene polymorphisms potentially related to the pharmacokinetics of clozapine
  125. Psychiatric side effects of acute high-dose corticosteroid therapy in neurological conditions
  126. Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders
  127. Trends in the use of antipsychotics in the Israeli inpatient population, 2004–2013
  128. Cigarette Smoking, Alcohol and Cannabis Use in Patients With Pervasive Developmental Disorders
  129. Do Antidepressants Induce Psychosis in Children and Adolescents? A Naturalistic Study in Ambulatory Pediatric Population
  130. The clock-drawing test as a possible indicator of acute psychosis
  131. Group cognitive behavioral treatment in female soldiers diagnosed with binge/purge eating disorders
  132. Adherence to Antidepressants Is Associated With Lower Mortality
  133. Methadone treatment, bruxism, and temporomandibular disorders among male prisoners
  134. The association between serum creatine kinase, mood and psychosis in inpatients with schizophrenia, bipolar and schizoaffective disorders
  135. CHRNA5/A3/B4Variant rs3743078 and Nicotine-Related Phenotypes: Indirect Effects Through Nicotine Craving
  136. The CD44 ligand hyaluronic acid is elevated in the cerebrospinal fluid of suicide attempters and is associated with increased blood–brain barrier permeability
  137. Periodic patterning of the Drosophila eye is stabilized by the diffusible activator Scabrous
  138. Elevated C-reactive protein levels in schizophrenia inpatients is associated with aggressive behavior
  139. Seasonal pattern of manic episode admissions among bipolar I disorder patients is associated with male gender and presence of psychotic features
  140. Treatment of Antipsychotic-Related Akathisia Revisited
  141. Quinazoline-based tricyclic compounds that regulate programmed cell death, induce neuronal differentiation, and are curative in animal models for excitotoxicity and hereditary brain disease
  142. Attenuated Weight Gain with the Novel Analog of Olanzapine Linked to Sarcosinyl Moiety (PGW5) Compared to Olanzapine
  143. Impact of epilepsy and antiepileptic medications on the metabolic profile in adults with autism spectrum disorder and intellectual disabilities
  144. Dehydroepiandrosterone Attenuates Cocaine-Seeking Behaviour Independently of Corticosterone Fluctuations
  145. The Association in Elderly Hospitalized Patients, Between Psychotropic Drugs and Hip Fractures Resulting from Falls
  146. The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth
  147. Authors' reply
  148. Effects of long-term valproic acid treatment on hematological and biochemical parameters in adolescent psychiatric inpatients
  149. P.2.d.002 Seasonal pattern of manic episode admissions among bipolar I disorder patients is associated with male gender and higher rates of psychotic features
  150. P.3.d.027 The risk for readmission in schizophrenia patients treated with long-acting injectable (typical or atypical) versus oral antipsychotics
  151. P.2.b.014 The use of smartphone app for early detection of manic or depressive episodes in affective patients
  152. Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder
  153. A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder
  154. The Impact of Chronic Early Administration of Psychostimulants on Brain Expression of BDNF and Other Neuroplasticity-Relevant Proteins
  155. The impact of age and gender on adherence to antidepressants: a 4-year population-based cohort study
  156. Intracranial pancreatic islet transplantation increases islet hormone expression in the rat brain and attenuates behavioral dysfunctions induced by MK-801 (dizocilpine)
  157. Post-SSRI Sexual Dysfunction
  158. Baclofen as Add-On to Standard Psychosocial Treatment for Alcohol Dependence: a Randomized, Double-Blind, Placebo-Controlled Trial With 1Year Follow-Up
  159. Immunomodulatory activity of ketamine in human astroglial A172 cells: Possible relevance to its rapid antidepressant activity
  160. High Familial Correlation in Methylphenidate Response and Side Effect Profile
  161. Alterations in brain neurotrophic and glial factors following early age chronic methylphenidate and cocaine administration
  162. Cognitive Decline Preceding the Onset of Psychosis in Patients With 22q11.2 Deletion Syndrome
  163. Effect of dehydroepiandrosterone add-on therapy on mood, decision making and subsequent relapse of polydrug users
  164. Adherence to antidepressant therapy and mortality rates in ischaemic heart disease: cohort study
  165. The complex Impact of Five Years of Stress Related to Life-Threatening Events on Pregnancy Outcomes: A Preliminary Retrospective Study
  166. SSRI-Induced Activation Syndrome in Children and Adolescents—What Is Next?
  167. Hyperactive auditory processing in Williams syndrome: Evidence from auditory evoked potentials
  168. Thymic and bone marrow output in individuals with 22q11.2 deletion syndrome
  169. Effect of Clozapine and Other Antipsychotics on the Level of Platelet-Associated Autoantibodies in Children with Schizophrenia: A Longitudinal Follow-Up Study
  170. Pharmacological and behavioral management of some often-overlooked clozapine-induced side effects
  171. Short-Term Effects of Lithium on White Blood Cell Counts and on Levels of Serum Thyroid-Stimulating Hormone and Creatinine in Adolescent Inpatients: A Retrospective Naturalistic Study
  172. International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder
  173. Opposing Effects of Oxytocin on Overt Compliance and Lasting Changes to Memory
  174. Abstract A76: Ras pathway and HIF-1α contribute to the aggressiveness of Ewing sarcoma
  175. P.2.h.003 Religiosity decreases self-injurious thoughts and behaviours in Jewish adolescents: findings from a nationally representative survey
  176. Religiosity is a protective factor against self-injurious thoughts and behaviors in Jewish adolescents: Findings from a nationally representative survey
  177. The Beneficial Effect of Trazodone Treatment on Escitalopram-Associated Nocturnal Bruxism
  178. Intrusive trauma recollections is associated with impairment of interference inhibition and psychomotor speed in PTSD
  179. P.2.d.004 Association between bipolar episodes and fluid and electrolyte homeostasis: a retrospective longitudinal study
  180. P.1.a.006 Decreased A-to-I RNA editing levels in the brains of schizophrenia patients: a possible biomarker
  181. Bruxism and oral parafunctional hyperactivity in social phobia outpatients
  182. Association of COMT and PRODH gene variants with intelligence quotient (IQ) and executive functions in 22q11.2DS subjects
  183. Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia
  184. Metabolic profiles in adults with autism spectrum disorder and intellectual disabilities
  185. Parental Alcohol History Differentially Predicts Offspring Disorders in Distinct Subgroups in Israel
  186. The beneficial effect of escitalopram on obsessive–compulsive-related musical hallucinations in elderly patients with hearing impairment
  187. The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety
  188. Association between bipolar episodes and fluid and electrolyte homeostasis: a retrospective longitudinal study
  189. Parental psychopathology moderates the influence of parental divorce on lifetime alcohol use disorders among Israeli adults
  190. Effects of the Anti-Multiple Sclerosis Immunomodulator Laquinimod on Anxiety and Depression in Rodent Behavioral Models
  191. Alcohol Consumption Mediates the Relationship BetweenADH1Band DSM-IV Alcohol Use Disorder and Criteria
  192. Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia
  193. Psychiatric Disorders From Childhood to Adulthood in 22q11.2 Deletion Syndrome: Results From the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome
  194. Corrigendum to ‘Exposure to the Lebanon War of 2006 and effects on alcohol use disorders: The moderating role of childhood maltreatment’ [Drug Alcohol Depend. 134 (2014) 296–303]
  195. Adherence to antidepressants is associated with lower mortality: A four-year population-based cohort study
  196. A comparative study of the neuropsychiatric and neurocognitive phenotype in two microdeletion syndromes: Velocardiofacial (22q11.2 deletion) and Williams (7q11.23 deletion) syndromes
  197. Metabolic Effects of Antipsychotics in Prepubertal Children: A Retrospective Chart Review
  198. Trauma exposure, posttraumatic stress disorder and risk for alcohol, nicotine, and marijuana dependence in Israel
  199. A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia
  200. Biological Effects of COMT Haplotypes and Psychosis Risk in 22q11.2 Deletion Syndrome
  201. Working memory dysfunction in schizophrenia patients with obsessive-compulsive symptoms: An fMRI study
  202. In vitro effect of FGIN-1-27, a ligand to 18 kDa mitochondrial translocator protein, in human osteoblast-like cells
  203. Shyness discriminates between children with 22q11.2 deletion syndrome and Williams syndrome and predicts emergence of psychosis in 22q11.2 deletion syndrome
  204. Cognitive traits in inpatient adolescents with and without prior suicide attempts and non-suicidal self-injury
  205. The effect of endothelial cells on hESC-derived pancreatic progenitors in a 3D environment
  206. Exposure to the Lebanon War of 2006 and effects on alcohol use disorders: The moderating role of childhood maltreatment
  207. Acute manic episode is associated with an increased risk of lower limb edema
  208. Dominant negative DISC1 mutant mice display specific social behaviour deficits and aberration in BDNF and cannabinoid receptor expression
  209. Interactions between risky decisions, impulsiveness and smoking in young tattooed women
  210. Risk Factors and the Evolution of Psychosis in 22q11.2 Deletion Syndrome: A Longitudinal 2-Site Study
  211. Schizophrenia-like neurophysiological abnormalities in 22q11.2 deletion syndrome and their association to COMT and PRODH genotypes
  212. miR-192 Directly Binds and Regulates Dicer1 Expression in Neuroblastoma
  213. Childhood adversity moderates the effect ofADH1Bon risk for alcohol-related phenotypes in Jewish Israeli drinkers
  214. Alcohol Dependence and Suicide-Related Ideation/Behaviors in an Israeli Household Sample, With and Without Major Depression
  215. Hematological and Cardiometabolic Safety of Clozapine in the Treatment of Very Early Onset Schizophrenia: A Retrospective Chart Review
  216. Gender differences in emotional and behavioral disorders and service use among adolescent smokers: A nationwide Israeli study
  217. Mesenchymal stem cells protect from sub-chronic phencyclidine insult in vivo and counteract changes in astrocyte gene expression in vitro
  218. Executive attention deficits in schizophrenia: Putative mandatory and differential cognitive pathology domains in medicated schizophrenia patients
  219. Neuroprotective and procognitive effects of sertraline: In vitro and in vivo studies
  220. Safety of phosphatidylserine containing omega3 fatty acids in ADHD children: A double-blind placebo-controlled trial followed by an open-label extension
  221. The interaction of subjective experience and attitudes towards specific antipsychotic-related adverse effects in schizophrenia patients
  222. Alcohol-Metabolizing Genes and Alcohol Phenotypes in an Israeli Household Sample
  223. Association between a common CYP17A1 haplotype and anxiety in female anorexia nervosa
  224. The use of mental health services by adolescent smokers: A nationwide Israeli study
  225. Erratum to "Adherence to antipsychotic drug treatment in early-episode schizophrenia: A six- month naturalistic follow-up study” [Schizophrenia Research, 130 (2011), 176-181]
  226. Enhanced Maternal Origin of the 22q11.2 Deletion in Velocardiofacial and DiGeorge Syndromes
  227. Neonatal stress modulates sickness behavior: Role for proinflammatory cytokines
  228. In vitro catabolic effect of protoporphyrin IX in human osteoblast-like cells: possible role of the 18 kDa mitochondrial translocator protein
  229. Additive Effects of 5-HTTLPR (Serotonin Transporter) and Tryptophan Hydroxylase 2 G-703T Gene Polymorphisms on the Clinical Response to Citalopram among Children and Adolescents with Depression and Anxiety Disorders
  230. Enhanced Maternal Origin of the 22q11.2 Deletion in Velocardiofacial and DiGeorge Syndromes
  231. Escitalopram in the treatment of patients with schizophrenia and obsessive–compulsive disorder
  232. Suicidal Thoughts Are Associated with Platelet Counts in Adolescent Inpatients
  233. Validity of proposed DSM-5 diagnostic criteria for nicotine use disorder: results from 734 Israeli lifetime smokers
  234. Mental disorders in primary care in Israel: prevalence and risk factors
  235. Attention-Deficit/Hyperactivity Disorder and Comorbid Subsyndromal Depression
  236. High Circulatory Titer of Platelet-Associated Autoantibodies in Childhood Onset Schizophrenia and Its Diagnostic Implications
  237. Reboxetine Treatment for Autistic Spectrum Disorder of Pediatric Patients With Depressive and Inattentive/Hyperactive Symptoms
  238. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Safety, and Tolerability of Extended-Release Metadoxine in Adults With Attention-Deficit/Hyperactivity Disorder
  239. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine–betahistine combination
  240. Genotype-phenotype correlation in 22q11.2 deletion syndrome
  241. Alcohol Use Disorders and Perceived Drinking Norms: Ethnic Differences in Israeli Adults
  242. Outcomes of compulsorily admitted schizophrenia patients who agreed or disagreed to prolong their hospitalization
  243. Rate of readmission and mortality risks of schizophrenia patients who were discharged against medical advice
  244. S.26.03 Metadoxine: a novel non-stimulant extended-release drug for treating ADHD
  245. The Effects of Reboxetine Treatment on Depression-like Behavior, Brain Neurotrophins, and ERK Expression in Rats Exposed to Chronic Mild Stress
  246. Olfactory function and alternation learning in eating disorders
  247. Handshaking as a measure of social responsiveness in patients with autistic spectrum disorder
  248. Perfectionism, narcissism, and depression in suicidal and nonsuicidal adolescent inpatients
  249. Emerging Association Between Addictive Gaming and Attention-Deficit/Hyperactivity Disorder
  250. Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications
  251. Low self-awareness of ADHD in adults using a self-report screening questionnaire
  252. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: A double-blind placebo-controlled trial, followed by an open-label extension
  253. The influence of DHEA pretreatment on prepulse inhibition and the HPA-axis stress response in rat offspring exposed prenatally to polyriboinosinic–polyribocytidylic-acid (PIC)
  254. The feasibility and safety of S-adenosyl-l-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial
  255. Age-of-onset of schizophrenic and obsessive-compulsive symptoms in patients with schizo-obsessive disorder
  256. Antipsychotic monotherapy and adjuvant psychotropic therapies in schizophrenia patients
  257. Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients?
  258. Theory of mind, severity of autistic symptoms and parental correlates in children and adolescents with Asperger syndrome
  259. Self versus maternal reports of emotional and behavioral difficulties in suicidal and non-suicidal adolescents: An Israeli nationwide survey
  260. Association between tobacco smoking and bipolar affective disorder: clinical, epidemiological, cross-sectional, retrospective study in outpatients
  261. The Factors Influencing Decision Making on Children’s Psychiatric Hospitalization: A Retrospective Chart Review
  262. Immunomodulatory Effect of Sertraline in a Rat Model of Rheumatoid Arthritis
  263. Antidepressant Treatment for Acute Bipolar Depression: An Update
  264. Are Names of Children with Attention Deficit Hyperactivity Disorder More ‘Hyperactive’
  265. Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs
  266. Rivastigmine Treatment for the Prevention of Electroconvulsive Therapy–Induced Memory Deficits in Patients With Schizophrenia
  267. Late potentials in the signal-averaged electrocardiogram in pre-pubertal children with ADHD, before and after methylphenidate treatment
  268. Intracerebral adult stem cells transplantation increases brain-derived neurotrophic factor levels and protects against phencyclidine-induced social deficit in mice
  269. Methadone maintenance and cancer risk: An Israeli case registry study
  270. The Effect of Methylphenidate on Prefrontal Cognitive Functioning, Inattention, and Hyperactivity in Velocardiofacial Syndrome
  271. In vitro mitochondrial effects of PK 11195, a synthetic translocator protein 18 kDa (TSPO) ligand, in human osteoblast-like cells
  272. Peptide-binding GRP78 protects neurons from hypoxia-induced apoptosis
  273. Phenotypic psychiatric characterization of children with Williams syndrome and response of those with ADHD to methylphenidate treatment
  274. Parental bonding in severely suicidal adolescent inpatients
  275. Predictors of clozapine discontinuation in patients with schizophrenia
  276. Effectiveness and Safety of Citalopram in Hospitalized Adolescents With Major Depression
  277. Nicotine dependence, abuse and craving: dimensionality in an Israeli sample
  278. Adherence to antipsychotic drug treatment in early-episode schizophrenia: A six-month naturalistic follow-up study
  279. Platelet Vesicular Monoamine Transporter 2 Density in the Disruptive Behavior Disorders
  280. Gonadal steroids and affective symptoms during in vitro fertilization: Implication for reproductive mood disorders
  281. Serum Levels of Brain-Derived Neurotrophic Factor and Cortisol to Sulfate of Dehydroepiandrosterone Molar Ratio Associated With Clinical Response to l-Theanine as Augmentation of Antipsychotic Therapy in Schizophrenia and Schizoaffective Disorder Patients
  282. When Does It End? Attention-Deficit/Hyperactivity Disorder in the Middle Aged and Older Populations
  283. Level of Function at Discharge as a Predictor of Readmission Among Inpatients With Schizophrenia
  284. Methylphenidate Treatment in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder and Comorbid Trichotillomania
  285. Trends in prescribing of psychotropic medications for inpatient adolescents in Israel: A 10 years retrospective analysis
  286. Altered affinity of the platelet vesicular monoamine transporter 2 to dihydrotetrabenazine in children with major depression
  287. The Effects of Fluoxetine Treatment in a Chronic Mild Stress Rat Model on Depression-Related Behavior, Brain Neurotrophins and ERK Expression
  288. Cognitive Behavior Therapy for Social Phobia in Large Groups
  289. Evaluation of Side Effects using the BARS, SAS and AIMS in Pediatric Psychopharmacologic Studies
  290. Level of training of nursing staff and the autonomy given to psychiatric inpatients: a multicenter study
  291. The usage of new antipsychotics in treatment of schizophrenia with obsessive-compulsive symptoms
  292. Mirtazapine – A Multifunctional Drug: Low Dose for Akathisia
  293. GnRH-agonist induced depressive and anxiety symptoms during in vitro fertilization–embryo transfer cycles
  294. Low-Dose Quetiapine for Adolescents With Autistic Spectrum Disorder and Aggressive Behavior
  295. The Immunomodulatory Effect of the Antidepressant Sertraline in an Experimental Autoimmune Encephalomyelitis Mouse Model of Multiple Sclerosis
  296. Schizophrenia Spectrum Disorders and Risk for Cancer Morbidity and Mortality
  297. The role of dehydroepiandrosterone (DHEA) in drug-seeking behavior
  298. The effect of chronic methylphenidate administration on presynaptic dopaminergic parameters in a rat model for ADHD
  299. Association of polymorphisms of the serotonergic pathways with clinical traits of impulsive-aggression and suicidality in adolescents: A multi-center study
  300. Monitoring of Circadian Rhythms of Heart Rate, Locomotor Activity, and Temperature for Diagnosis and Evaluation of Response to Treatment in an Animal Model of Depression
  301. Trazodone for the Treatment of Neuroleptic-Induced Acute Akathisia
  302. In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells
  303. S.03.04 An alternative approach to antipsychotic activity: the metabotropic glutamatergic receptor
  304. Alterations in QT dispersion in the surface electrocardiogram of female adolescent inpatients diagnosed with bulimia nervosa
  305. Pregnenolone and Dehydroepiandrosterone as an Adjunctive Treatment in Schizophrenia and Schizoaffective Disorder
  306. Lack of modulatory effect of short-term repeated electroconvulsive therapy on platelet vesicular monoamine transporter 2 (VMAT2) in depressed patients
  307. Fear Thou Not: Activity of Frontal and Temporal Circuits in Moments of Real-Life Courage
  308. A Review of: “The Oxford Textbook of Suicidology and Suicide Prevention: A Global Perspective”
  309. Possible association between attention deficit hyperactivity disorder and attempted suicide in adolescents – A pilot study
  310. Stroop performance in major depression: Selective attention impairment or psychomotor slowness?
  311. WORKING MEMORY IMPAIRMENTS IN SCHIZOPHRENIA AS VALID PREDICTORS OF ILNESS SEVERITY AND FUNCTIONAL OUTCOME
  312. Alteration learning in social anxiety disorder: An fMRI study
  313. Late potentials in the signal-averaged electrocardiogram in schizophrenia patients maintained on antipsychotic agents
  314. Microstructural evolution during the infiltration of boron carbide with molten silicon
  315. Stability of Schizoaffective Disorder in Correlation with Duration of Follow-Up: Retrospective Analysis
  316. Early Repolarization in Young Children with Attention-Deficit/Hyperactivity Disorder Versus Normal Controls: A Retrospective Preliminary Chart Review Study
  317. Psychiatric Disorders and Intellectual Functioning Throughout Development in Velocardiofacial (22q11.2 Deletion) Syndrome
  318. Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study
  319. Platelet poor plasma serotonin level in delinquent adolescents diagnosed with conduct disorder
  320. Proapoptotic and chemosensitizing effects of selective serotonin reuptake inhibitors on T cell lymphoma/leukemia (Jurkat) in vitro
  321. Personality characteristics and gonadal steroid manipulation in IVF treatments: predictors of successful outcome
  322. Association between corneal temperature and mental status of treatment-resistant schizophrenia inpatients
  323. β-Adrenergic Antagonists for the Treatment of Clozapine-Induced Sinus Tachycardia
  324. Influence of Methylphenidate Treatment on Smoking Behavior in Adolescent Girls With Attention-Deficit/Hyperactivity and Borderline Personality Disorders
  325. Attenuation of cue-induced smoking urges and brain reward activity in smokers treated successfully with bupropion
  326. DHEA and DHEA-S levels in hospitalized adolescents with first-episode schizophrenia and conduct disorder: A comparison study
  327. Efficacy of Reboxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Boys With Intolerance to Methylphenidate
  328. Reduced levels of miR-34a in neuroblastoma are not caused by mutations in theTP53binding site
  329. Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: A comparative double-blind study
  330. The Effect of Particle Size Distribution on the Microstructure and the Mechanical Properties of Boron Carbide-Based Reaction-Bonded Composites
  331. Effect of Implementing Dental Services in Israeli Psychiatric Hospitals on the Oral and Dental Health of Inpatients
  332. Rim region growth and its composition in reaction bonded boron carbide composites with core-rim structure
  333. γ-Aminobutyric Acid Amides of Nortriptyline and Fluoxetine Display Improved Pain Suppressing Activity
  334. An integrative quantitative model of factors influencing the course of anorexia nervosa over time
  335. Velocardiofacial Syndrome
  336. Priapism as an unusual manifestation of catatonia: A case report
  337. The risk for cancer among patients with schizoaffective disorders
  338. Attention-Deficit Hyperactivity Disorder, Methylphenidate, and Primary Encopresis
  339. Differences in audiovisual integration, as measured by McGurk phenomenon, among adult and adolescent patients with schizophrenia and age-matched healthy control groups
  340. Factors Determining Satisfaction in Psychiatry Training in Israel
  341. Impact of depression on treatment effectiveness and gains maintenance in social phobia: a naturalistic study of cognitive behavior group therapy
  342. Neuropsychological mechanisms of Digit Symbol Substitution Test impairment in Asperger Disorder
  343. Trazodone for the Treatment of Sexual Dysfunction Induced by Serotonin Reuptake Inhibitors
  344. P.3.15 Serum creatine kinase levels and neuromuscular dysfunction in psychiatric patients: new results of follow-up study
  345. Effect of Exposure to Selective Serotonin Reuptake Inhibitors In Utero on Fetal Growth: Potential Role for the IGF-I and HPA Axes
  346. Serum creatine kinase activity differentiates alcohol syndromes of dependence, withdrawal and delirium tremens
  347. BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia
  348. Altered thermoregulation in ambulatory schizophrenia patients: A naturalistic study
  349. Blind Verification of Elevated Platelet Autoantibodies in Serum of Schizophrenic Patients – Part I: Young Subjects
  350. Blind Verification of Elevated Platelet Autoantibodies in Serum of Schizophrenic Patients – Part II: Adult Subjects
  351. Improvement of aggressive behavior and quality of life impairment following S-Adenosyl-Methionine (SAM-e) augmentation in schizophrenia
  352. Monoamines, BDNF, Dehydroepiandrosterone, DHEA-Sulfate, and Childhood Depression—An Animal Model Study
  353. Neurosteroid blood levels in delinquent adolescent boys with conduct disorder
  354. Efficacy and Safety of N-3 Phosphatidylserine in Children with Attention Deficit and Hyperactivity Disorder (ADHD)
  355. Methylphenidate Treatment in ADHD/borderline Personality Disorder Adolescent Girls and Smoking Behavior
  356. Schizophrenia Endophenotypes as Treatment Targets
  357. Neuroprotective effect of Ro5-4864 following brain injury
  358. A cross-fostering study in a genetic animal model of depression: Maternal behavior and depression-like symptoms
  359. Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety
  360. The 18-kDa translocator protein, formerly known as the peripheral-type benzodiazepine receptor, confers proapoptotic and antineoplastic effects in a human colorectal cancer cell line
  361. Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol
  362. Disaster mental health in Asia and the Asian Journal of Psychiatry
  363. Hormonal Response to Dehydroepiandrosterone Administration in Schizophrenia
  364. In vivo occipital–frontal temperature-gradient in schizophrenia patients and its possible association with psychopathology: A magnetic resonance spectroscopy study
  365. P.6.c.005 Attenuation of cue-induced cigarette urges and brain activity in bupropion-treated smokers
  366. P.1.c.007 Serotonin pathway genes polymorphisms and the clinical response to citalopram among children and adolescents
  367. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial
  368. Relationship between antidepressants and IGF-1 system in the brain: Possible role in cognition
  369. The effect of DHEA complementary treatment on heroin addicts participating in a rehabilitation program: A preliminary study
  370. The possible involvement of metabotropic glutamate receptors in schizophrenia
  371. DHEA Lessens Depressive-Like Behavior via GABA-ergic Modulation of the Mesolimbic System
  372. A Mutual Prodrug Ester of GABA and Perphenazine Exhibits Antischizophrenic Efficacy with Diminished Extrapyramidal Effects
  373. Enhanced cancer risk among patients with bipolar disorder
  374. Sense of coherence among delusional patients: prediction of remission and risk of relapse
  375. Dehydroepiandrosterone and monoamines in the limbic system of a genetic animal model of childhood depression
  376. Does a Clerkship in Psychiatry Contribute to Changing Medical Students' Attitudes Towards Psychiatry?
  377. Evidence for an inhibitory immunomodulatory effect of selected antidepressants on rat splenocytes: Possible relevance to depression and hyperactive-immune disorders
  378. Recurrnet catatonia: Fluctuating between psychotic and catatonic dimensions
  379. Aripiprazole’s Receptor Pharmacology and Extrapyramidal Side Effects
  380. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study
  381. Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders
  382. Itching in the Psychiatric Ward
  383. Multi-modal weight control intervention for people with persistent mental disorders.
  384. The Impact of Mental Illness on Sexual Dysfunction
  385. The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production
  386. Ziprasidone: clinical properties and therapeutic promise
  387. Objective Versus Subjective Assessment of Methylphenidate Response
  388. CK levels in unmedicated bipolar patients
  389. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression
  390. Reboxetine Maintenance Treatment in Children with Attention-Deficit/Hyperactivity Disorder: A Long-Term Follow-Up Study
  391. Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness and Side Effects in Children with Depression and/or Anxiety Disorders
  392. Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases
  393. Dehydroepiandrosterone in the nucleus accumbens is associated with early onset of depressive-behavior: A study in an animal model of childhood depression
  394. Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS
  395. Risk of readmission in compulsorily and voluntarily admitted patients
  396. Effect of ADH1B Genotype on Alcohol Consumption in Young Israeli Jews
  397. Circulatory neurosteroid levels in smoking and non-smoking chronic schizophrenia patients
  398. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone
  399. Reduced platelet vesicular monoamine transporter density in Tourette's syndrome pediatric male patients
  400. Cognition, psychosocial adjustment and coping in familial cases of velocardiofacial syndrome
  401. Sildenafil citrate in the treatment of sexual dysfunction and its effect on quality of life in alcohol dependent men: preliminary findings
  402. A significant correlation between ward temperature and the severity of symptoms in schizophrenia inpatients — A longitudinal study
  403. Alterations in QT dispersion in the surface electrocardiogram of female adolescents diagnosed with restricting-type anorexia nervosa
  404. Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects
  405. Neurological Soft Signs in Schizophrenia Patients With Obsessive-Compulsive Disorder
  406. QT Interval and Dispersion in Very Young Children Treated with Antipsychotic Drugs: A Retrospective Chart Review
  407. State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients
  408. Prolactin and estradiol serum levels in unmedicated male paranoid schizophrenia patients
  409. Decreased platelet vesicular monoamine transporter binding capacity in tourette syndrome
  410. Objective versus subjective assessment of MPH response
  411. QT interval and dispersion in very young children treated with antipsychotic drugs
  412. The possible association, in adolescence, between attention deficit and hyperactivity disorder and attempted suicide – a pilot study
  413. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: A randomized, double-blind placebo controlled trial
  414. Association of the serotonin transporter promotor polymorphism with suicide attempters with a high medical damage
  415. Neurosteroids in child and adolescent psychopathology
  416. Serum creatine kinase level in unmedicated nonpsychotic, psychotic, bipolar and schizoaffective depressed patients
  417. A 10-year retrospective study of inpatient adolescents with schizophrenia/schizoaffective disorder and substance use
  418. Demographic and clinical characteristics of motor vehicle accident victims in the community general health outpatient clinic: a comparison of PTSD and non-PTSD subjects
  419. Depressed mood through women's reproductive cycle: correlation to mood at menopause
  420. Dual contribution of NR2B subunit of NMDA receptor and SK3 Ca2+-activated K+ channel to genetic predisposition to anorexia nervosa
  421. Psychological and cytokine changes in children and adolescents undergoing hematopoietic stem cell transplantation
  422. Serotonin transporter characteristics in lymphocytes and platelets of male aggressive schizophrenia patients compared to non-aggressive schizophrenia patients
  423. Aggressive behavior and HPA axis hormones after social isolation in adult rats of two different genetic animal models for depression
  424. Homocysteine levels in adolescent schizophrenia patients
  425. Substance Use, Suicidality, and Adolescent-Onset Schizophrenia: An Israeli 10-Year Retrospective Study
  426. Modulatory Effects of Thyroxine Treatment on Central and Peripheral Benzodiazepine Receptors in the Rat
  427. Electroconvulsive Therapy and Transcranial Magnetic Stimulation: Can They be Considered Valid Modalities in the Treatment of Pediatric Mood Disorders?
  428. Preferential Aggregation of Obsessive—Compulsive Spectrum Disorders in Schizophrenia Patients with Obsessive—Compulsive Disorder
  429. Stress hormones and emotion-regulation in two genetic animal models of depression
  430. The protective effect of frontal cortex dehydroepiandrosterone in anxiety and depressive models in mice
  431. The use of illicit substances in adolescent schizophrenia inpatients
  432. Erratum to “Involvement of GABAA receptor modulating neuroactive steroids in patients with social phobia” [Psychiatry Res. 137 (2005) 131–136]
  433. Cocaine, but not amphetamine, short term treatment elevates the density of rat brain vesicular monoamine transporter 2
  434. Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals
  435. An Open-Label Randomized Comparison of Olanzapine Versus Risperidone in the Treatment of Childhood-Onset Schizophrenia
  436. Impact of Gastric Banding on Plasma Adiponectin Levels
  437. Obsessive–compulsive disorder in bipolar disorder patients with first manic episode
  438. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function
  439. The Child in the Family of a Drug-Using Father: Attachment Styles and Family Characteristics
  440. Elevated platelet vesicular monoamine transporter 2 in former heroin addicts maintained on methadone
  441. Thyroxine-Triiodothyronine Combination TherapyVersusThyroxine Monotherapy for Clinical Hypothyroidism: Meta-Analysis of Randomized Controlled Trials
  442. Dehydroepiandrosterone (DHEA) attenuates cocaine-seeking behavior in the self-administration model in rats
  443. A complete genetic association scan of the 22q11 deletion region and functional evidence reveal an association between DGCR2 and schizophrenia
  444. Factors Associated with Self-evaluated Severity of Illness and Quality of Life in Male Israeli Asthmatic Soldiers
  445. Low-Dose Mirtazapine: A New Option in the Treatment of Antipsychotic-Induced Akathisia. A Randomized, Double-Blind, Placebo- and Propranolol-Controlled Trial
  446. Association of the low-activity COMT 158Met allele with ADHD and OCD in subjects with velocardiofacial syndrome
  447. The protective activity of brain dehydroepiandrosterone (DHEA) in behavioral disorders
  448. Reboxetine Versus Fluvoxamine in the Treatment of Motor Vehicle Accident-related Posttraumatic Stress Disorder
  449. The relevance of neurosteroids to clinical psychiatry: From the laboratory to the bedside
  450. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study
  451. Alterations in DHEA metabolism in schizophrenia: Two-month case-control study
  452. Effects of early-life stress on behavior and neurosteroid levels in the rat hypothalamus and entorhinal cortex
  453. Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder
  454. DHEA, a Neurosteroid, Decreases Cocaine Self-Administration and Reinstatement of Cocaine-Seeking Behavior in Rats
  455. A Six-Month Outcome of Long-Stay Inpatients Resettled in a Hostel.
  456. Clinical characteristics of inpatient adolescents with severe obsessive–compulsive disorder
  457. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study
  458. Obstetric complications in individuals diagnosed with autism and in healthy controls
  459. Plasma serotonin levels and suicidal behavior in adolescents
  460. Serotonin uptake to lymphocytes of patients with social phobia compared to normal individuals
  461. Two Different Putative Genetic Animal Models of Childhood Depression
  462. P.3.c.022 Amelioration of symptomatology, Parkinsonism and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in schizophrenia
  463. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth
  464. The effect of psychostimulants on [3H]dopamine uptake and release in rat brain synaptic vesicles
  465. Circulatory neurosteroid levels in underweight female adolescent anorexia nervosa inpatients and following weight restoration
  466. Life events and suicidality in adolescents with schizophrenia
  467. Pilot Study: Fluvoxamine Treatment for Depression and Anxiety Disorders in Children and Adolescents with Cancer
  468. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: A randomized, double-blind placebo controlled trial
  469. Haplotype analysis of theCOMT-ARVCFgene region in Israeli anorexia nervosa family trios
  470. The Relationship between BMI, Plasma Leptin, Insulin and Proinsulin Before and After Laparoscopic Adjustable Gastric Banding
  471. Memantine for Treatment-Resistant OCD
  472. Hormonal Profile Effects Following Dehydroepiandrosterone (DHEA) Administration to Schizophrenic Patients
  473. Involvement of GABAA receptor modulating neuroactive steroids in patients with social phobia
  474. Involvement of prostaglandins in an animal model of Shigella-related seizures
  475. Erratum to “Cancer in schizophrenia: Is the risk higher or lower?” [Schizophr. Res. 2005 Mar 1;73(2–3):333–41]
  476. Reduced platelet vesicular monoamine transporter density in smoking schizophrenia patients
  477. Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines
  478. Impact of Gastric Banding on Plasma Ghrelin, Growth Hormone, Cortisol, DHEA and DHEA-S Levels
  479. Platelet vesicular monoamine transporter density in untreated patients diagnosed with social phobia
  480. A95 DHEA ATTENUATES COCAINE-SEEKING BEHAVIOR IN THE SELF-ADMINISTRATION MODEL IN RATS
  481. B10 EFFECT OF SELECTED ANTIDEPRESSANTS ON INFLAMMATORY PROCESSES ASSOCIATED WITH MODEL OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE) IN MICE
  482. A83 NOVEL ANTIPSYCHOTIC WITH DOPAMINE ANTAGONISM AND GABAERGIC ACTIVITY
  483. The effect of 17β estradiol withdrawal on the level of brain and peripheral neurosteroids in ovarectomized rats
  484. Expressed Emotion: Relevance to Rehospitalization in Schizophrenia Over 7 Years
  485. Family-based association study of 5-HT2A receptor T102C polymorphism and suicidal behavior in Ashkenazi inpatient adolescents
  486. The Peripheral-Type Benzodiazepine Receptor and Tumorigenicity:  Isoquinoline Binding Protein (IBP) Antisense Knockdown in the C6 Glioma Cell Line†
  487. Corneal temperature in schizophrenia patients
  488. Dopamine transporter haplotype and attention-deficit hyperactivity disorder
  489. Cortisol/Dehydroepiandrosterone Ratio and Responses to Antipsychotic Treatment in Schizophrenia
  490. Errata
  491. Lowered DHEA-S plasma levels in adult individuals with autistic disorder
  492. Six-Week Open-Label Reboxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
  493. The involvement of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) in blocking the therapeutic effect of electroconvulsive shocks in an animal model of depression
  494. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia
  495. Ondansetron Treatment in Tourette's Disorder
  496. Reboxetine as an Optional Treatment for Hyperkinetic Conduct Disorder: A Prospective Open-Label Trial
  497. Cancer in schizophrenia: is the risk higher or lower?
  498. Decreased platelet vesicular monoamine transporter density in children and adolescents with attention deficit/hyperactivity disorder
  499. Decreased platelet vesicular monoamine transporter density in habitual smokers
  500. Is brain dehydroepiandrosterone synthesis modulated by free radicals in mice?
  501. Repeated swim stress leads to down-regulation of vesicular monoamine transporter 2 in rat brain nucleus accumbens and striatum
  502. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients
  503. Impaired procedural learning in obsessive?compulsive disorder and Parkinson's disease, but not in major depressive disorder
  504. Relationships between serotonin transporter promoter polymorphism, platelet serotonin transporter binding and clinical phenotype in suicidal and non-suicidal adolescent inpatients
  505. Reply to Problems in Assessing Musical Hallucination
  506. Effects of climate on admission rates of schizophrenia patients to psychiatric hospitals
  507. A Possible Antienuretic Effect of Reboxetine in Children and Adolescents with Attention Deficit/Hyperactivity Disorder: Case Series
  508. Familial aggregation of schizophrenia-spectrum disorders and obsessive-compulsive associated disorders in schizophrenia probands with and without OCD
  509. New drug targets for depression and anxiety: Is the peptides era arriving?
  510. The 5-HT1D receptor agonist zolmitriptan for neuroleptic-induced akathisia: an open label preliminary study
  511. P.3.07 Antipsychotic agents and neuromusculardysfunction
  512. Differential Induction of Apoptosis by Antidepressants in Glioma and Neuroblastoma Cell Lines: Evidence for p-c-Jun, Cytochrome c, and Caspase-3 Involvement
  513. P.2.014 The effect of DHEA administrationon extrapyramidal symptoms in schizophrenia: A randomized double blind placebo controlled trial
  514. A Case of Hyponatremia Associated With Escitalopram
  515. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology
  516. Psychosocial situations, quality of depression and schizophrenia in adolescents
  517. CAG repeat polymorphism within theKCNN3 gene is a significant contributor to susceptibility to anorexia nervosa: A case-control study of female patients and several ethnic groups in the Israeli Jewish population
  518. P.1.057 Characterization of the serotonin transporterand its modulation by antidepressants in peripheral blood lymphocytes
  519. P5.014 Decreased platelet vesicular monoaminetransporter density in habitual smokers
  520. P.2.052 Electroencephalographic changes in chronic neuroleptic-resistant schizophrenia patients during clozapine treatment
  521. P.2.082 Neuromuscular dysfunction in neuroleptics-treatedpsychiatric patients
  522. P.1.075 SSRI's therapy in depressive outpatients:Personality changes and predictors of response
  523. Influence of 17β-estradiol on the synthesis of reduced neurosteroids in the brain (in vivo) and in glioma cells (in vitro): possible relevance to mental disorders in women
  524. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients
  525. Dimensional complexity of the neuronal activity in a rat model of depression
  526. Involvement of the neuropeptide corticotropin-releasing hormone in an animal model of Shigella-related seizures
  527. Peripheral-type benzodiazepine receptor density and in vitro tumorigenicity of glioma cell lines
  528. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study
  529. The utility of the Visual Analogue Scale for the assessment of depressive mood in cognitively impaired patients
  530. Beneficial Effects of Gonadotropin-Releasing Hormone Analogue Treatment on Positive and Negative Symptoms of Schizophrenia
  531. Complexity of the dynamic QT variability and RR variability in patients with acute anterior wall myocardial infarction
  532. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study
  533. Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes
  534. DRD4 receptor gene exon III polymorphism in inpatient suicidal adolescents
  535. Mianserin for the rapid improvement of chronic akathisia in a schizophrenia patient
  536. Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes
  537. COMT: A common susceptibility gene in bipolar disorder and schizophrenia
  538. D2 Antagonist Augmentation in Patients with a Partial Response to Atypical Antipsychotics
  539. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus
  540. Electroconvulsive therapy in adolescent and adult psychiatric inpatients—a retrospective chart design
  541. Alterations in QT dispersion in medicated schizophrenia patients following electroconvulsive therapy
  542. Chronic lithium treatment affects rat brain and serum dehydroepiandrosterone (DHEA) and DHEA-sulphate (DHEA-S) levels
  543. Clozapine in the Treatment of Obsessive-compulsive Symptoms in Schizophrenia Patients: A Case Series Study
  544. Cysteine-induced hypoglycemic brain damage: an alternative mechanism to excitotoxicity
  545. Heart Rate Variability in Patients With Major Depression
  546. Personalized psychiatry: a realistic goal
  547. The relation between latent inhibition and symptom-types in young schizophrenics
  548. Musical Hallucinations: Prevalence in Psychotic and Nonpsychotic Outpatients
  549. Admission rates of bipolar depressed patients increase during spring/summer and correlate with maximal environmental temperature
  550. An Open-Label Trial of Sildenafil Addition in Risperidone-Treated Male Schizophrenia Patients With Erectile Dysfunction
  551. Obsessive-Compulsive Disorder in Schizophrenia
  552. Benefit-Risk Assessment of Atypical Antipsychotics in the Treatment of Schizophrenia and Comorbid Disorders in Children and Adolescents
  553. Characterization of Phenothiazine-Induced Apoptosis in Neuroblastoma and Glioma Cell Lines: Clinical Relevance and Possible Application for Brain-Derived Tumors
  554. Heart rate variability increases in elderly depressed patients who respond to electroconvulsive therapy
  555. Lack of Plasma Norepinephrine Cyclicity, Increased Estradiol during the Follicular Phase, and of Progesterone and Gonadotrophins at Ovulation in Women with Premenstrual Syndrome
  556. Low Platelet-Poor Plasma Levels of Serotonin in Adult Autistic Patients
  557. QT dispersion in patients with social phobia
  558. Sexual Dimorphism in obsessive-compulsive disorder
  559. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology
  560. The Influence of Parturition on the Level and Synthesis of Sulfated and Free Neurosteroids in Rats
  561. P.3.18 Rivastigmine therapy for memory deficits in schizophrenia patients receiving electroconvulsive treatment
  562. Defense Mechanisms in a Community-Based Sample of Female Adolescents with Partial Eating Disorders
  563. Granulocytopenia associated with neuroleptic therapy in a patient with benign familial leukopenia
  564. NQO2 gene is associated with clozapine-induced agranulocytosis
  565. Comparison of Clinical Characteristics and Comorbidity in Schizophrenia Patients With and Without Obsessive-Compulsive Disorder
  566. Decreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patients
  567. Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Velocardiofacial Syndrome
  568. Brain neurosteroid changes after paroxetine administration in mice
  569. Variability of Color Choice in the Lüscher Color Test—Sex Differences
  570. P.2.001 The effects of antipsychotic agents on sceletal muscle of psychiatric patients as it evidences by their serum creatine kinase activity
  571. Comparison of ego defenses among physically abused children, neglected, and non-maltreated children
  572. Effectiveness, Safety, and Tolerability of Risperidone in Adolescents with Schizophrenia: An Open-Label Study
  573. Olanzapine Treatment in Chronic Drug-Resistant Childhood-Onset Schizophrenia: An Open-Label Study
  574. Risperidone, but Not Olanzapine, Decreases Bone Mineral Density in Female Premenopausal Schizophrenia Patients
  575. The Effects of Clozapine Versus Haloperidol on Measures of Impulsive Aggression and Suicidality in Chronic Schizophrenia Patients
  576. Depression and suicidal behavior in adolescent inpatients with obsessive compulsive disorder
  577. Selegiline in the Treatment of Sexual Dysfunction in Schizophrenic Patients Maintained on Neuroleptics: A Pilot Study
  578. Efficacy of Low-Dose Mirtazapine in Neuroleptic-Induced Akathisia: A Double-Blind Randomized Placebo-Controlled Pilot Study
  579. Olanzapine-Sertraline Combination in Schizophrenia With Obsessive-Compulsive Disorder
  580. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study
  581. Oral health and treatment needs of institutionalized chronic psychiatric patients in Israel
  582. Precautionary measures reduce risk of definite neuroleptic malignant syndrome in newly typical neuroleptic-treated schizophrenia inpatients
  583. Treatment of Neuroleptic-Induced Akathisia With the 5-HT2A Antagonist Trazodone
  584. Bidirectional Concentration-Dependent Effects of Tumor Necrosis Factor Alpha in Shigella dysenteriae-Related Seizures
  585. Alternation learning in OCD/schizophrenia patients
  586. Amantadine as augmentation therapy in the management of treatment-resistant depression
  587. Decreased limbic vesicular monoamine transporter 2 in a genetic rat model of depression
  588. Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine
  589. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study
  590. The incidence of the serum creatine kinase elevation in schizophrenia and schizoaffective patients during antipsychotic treatment
  591. Attenuation of Olanzapine-Induced Weight Gain With Reboxetine in Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study
  592. Dehydroepiandrosterone Augmentation in the Management of Negative, Depressive, and Anxiety Symptoms in Schizophrenia
  593. Beneficial Effect of Donepezil Augmentation for the Management of Comorbid Schizophrenia and Dementia
  594. Clozapine decreases rat brain dehydroepiandrosterone and dehydroepiandrosterone sulfate levels
  595. Increased corneal temperature in drug-free male schizophrenia patients
  596. Lower Corneal Temperature in Neuroleptic-Treated vs. Drug-Free Schizophrenia Patients
  597. Neuroimaging communality between schizophrenia and obsessive compulsive disorder: A putative basis for schizo-obsessive disorder?
  598. Plasma Testosterone Levels in Patients with Combat-Related Posttraumatic Stress Disorder
  599. Platelet-Associated Antibodies Mediate Protective Autoimmune Response in Schizophrenia
  600. Sildenafil for Selective Serotonin Reuptake Inhibitor-Induced Erectile Dysfunction in Elderly Male Depressed Patients
  601. Substantial increase in number and dosage of antipsychotics in non-responsive vs. responsive schizophrenia inpatients
  602. The Drug-User Husband and His Wife: Attachment Styles, Family Cohesion, and Adaptability
  603. The platelet-poor plasma 5-HT response to carbohydrate rich meal administration in adult autistic patients compared with normal controls
  604. Three-Month Treatment Course of Methylphenidate Increases Plasma Levels of Dehydroepiandrosterone (DHEA) and Dehydroepiandrosterone-Sulfate (DHEA-S) in Attention Deficit Hyperactivity Disorder
  605. A Highly Significant Association between a COMT Haplotype and Schizophrenia
  606. Elevated platelet vesicular monoamine transporter density in untreated patients diagnosed with major depression
  607. Individual and familial psychopathology among hospitalized minors at risk, juvenile delinquents, and psychiatric controls
  608. Sexual Function and Behavior in Social Phobia
  609. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: A double-blind randomized placebo-controlled pilot study
  610. Association between flupenthixol treatment and emergence of manic symptoms
  611. Antipsychotic agents and serum creatine kinase levels
  612. Increased platelet vesicular monoamine transporter density in untreated major depressed patients
  613. Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients
  614. Use of dehydroepiandrosterone in the management of negative symptoms of schizophrenia
  615. Anticholinergic Burden and the Risk of Falls Among Elderly Psychiatric Inpatients: A 4-Year Case-Control Study
  616. Ziprasidone Alternative for Olanzapine-Induced Hyperglycemia
  617. Serum Creatine Kinase Levels in Untreated Hospitalized Adolescents During Acute Psychosis
  618. Increased platelet vesicular monoamine transporter density in adult schizophrenia patients
  619. Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2
  620. High Serum Creatinine Kinase Level: Possible Risk Factor for Neuroleptic Malignant Syndrome
  621. Olanzapine-Induced Weight Gain in Patients With First-Episode Schizophrenia: A Double-Blind, Placebo-Controlled Study of Fluoxetine Addition
  622. Weight Gain Associated With Increased Food Intake and Low Habitual Activity Levels in Male Adolescent Schizophrenic Inpatients Treated With Olanzapine
  623. Head circumference and incident Alzheimer's disease: Modification by apolipoprotein E
  624. An association of CAG repeats at the KCNN3 locus with symptom dimensions of schizophrenia
  625. Psychiatric comorbidity in schizophrenia with obsessive compulsive disorder
  626. Seasonality of birth in patients with type 1 diabetes
  627. The NR2B subunit of glutamate receptors as a potential target for relieving chronic pain: prospects and concerns
  628. Seasonality of birth in patients with type 1 diabetes
  629. Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia
  630. PK 11195 attenuates kainic acid-induced seizures and alterations in peripheral-type benzodiazepine receptor (PBR) protein components in the rat brain
  631. SOCIODEMOGRAPHIC FACTORS ASSOCIATED WITH ATTEMPTED SUICIDE IN TWO ISRAELI CITIES BETWEEN 1990 AND 1998
  632. Enhancement of pentylenetetrazole-induced seizures by Shigella dysenteriae in LPS-resistant C3H/HeJ mice: role of the host response
  633. Association between anorexia nervosa and the hsKCa3 gene: a family-based and case control study
  634. Familial Expressed Emotion: Outcome and Course of Israeli Patients With Schizophrenia
  635. Preferential transmission of interleukin-1 receptor antagonist alleles in attention deficit hyperactivity disorder
  636. Safety and efficacy of long-term low-dose clozapine aftercare treatment in a patient with learning difficulties who suffered from neuroleptic malignant syndrome
  637. Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study
  638. Sildenafil Citrate for the Sexual Dysfunction in Antidepressant-Treated Male Patients with Posttraumatic Stress Disorder
  639. Association between severity of schizophrenic symptoms and urinary retention
  640. Attachment Styles and Aggression in Physically Abused and Neglected Children
  641. Cyproheptadine Versus Propranolol for the Treatment of Acute Neuroleptic-Induced Akathisia: A Comparative Double-Blind Study
  642. Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson’s disease
  643. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells
  644. Acute and Repeated Swim Stress Effects on Peripheral Benzodiazepine Receptors in the Rat Hippocampus, Adrenal, and Kidney,
  645. Fatty acid amide hydrolase inhibitors and the marijuana debate
  646. Stability of diagnosis: a 20-year retrospective cohort study of Israeli psychiatric adolescent inpatients
  647. Analysis of neurosteroid levels in attention deficit hyperactivity disorder
  648. Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter
  649. Zuclopenthixol Treatment of Behavioral Disturbances in Mentally Retarded Children and Adolescents: An Open-Label Study
  650. Abnormal thermoregulation in drug-free male schizophrenia patients
  651. Animal models and human genome diversity: the pitfalls of inbred mice
  652. Effectiveness of dynamic cognitive intervention in rehabilitation of clients with schizophrenia
  653. Hormonal Regulation of Peripheral Benzodiazepine Receptor Binding Properties Is Mediated by Subunit Interaction
  654. Comparison of Sexual Dysfunction in Male Schizophrenic Patients Maintained on Treatment With Classical Antipsychotics Versus Clozapine
  655. Response of Catatonia to Risperidone: Two Case Reports
  656. Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: A new approach to an old problem
  657. Use and cost of outpatient visits of AD patients: CERAD XXII
  658. Heart Rate Variability in Elderly Patients Before and After Electroconvulsive Therapy
  659. Obsessive–compulsive disorder in hospitalized patients with chronic schizophrenia
  660. Geriatric Depression Scale (GDS-15): A Sensitive and Convenient Instrument for Measuring Depression in Young Anorexic Patients
  661. Mirtazapine for Neuroleptic-Induced Akathisia
  662. Metabolic bioenergy homeostatic disruption: a cause of anorexia nervosa
  663. Modeling the Volcanism on Mars
  664. Risperidone-Induced Retrograde Ejaculation
  665. Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients
  666. Subjective effects of MDMA (‘Ecstasy’) on human sexual function
  667. Familial Approach To The Treatment Of Childhood Obesity: Conceptual Model
  668. Obsessive-Compulsive Schizophrenia: A New Diagnostic Entity?
  669. Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine
  670. Case control and family-based studies of tryptophan hydroxylase gene A218C polymorphism and suicidality in adolescents
  671. Changes in Vesicular Monoamine Transporter (VMAT2) and Synaptophysin in Rat Substantia nigra and Prefrontal Cortex Induced by Psychotropic Drugs
  672. Depressive symptoms and suicidality in physically abused children.
  673. Family-based association study of serotonin transporter promoter in suicidal adolescents: No association with suicidality but possible role in violence traits
  674. Insulin, Insulin-like Growth Factors-I and -II and Insulin-like Growth Factor Binding Protein-3 in Newborn Serum: Association with Normal Fetal Head Growth and Head Circumference
  675. Plasma serotonin response to carbohydrate-rich food in chronic schizophrenic patients: clozapine versus classic antipsychotic agents
  676. The influence of three months of methylphenidate treatment on platelet-poor plasma biogenic amine levels in boys with attention deficit hyperactivity disorder
  677. Viewpoint: Obsessive Compulsive Behaviour in Autism - Towards an Autistic-Obsessive Compulsive Syndrome?
  678. The Antiaggressive Action of Combined Haloperidol-Propranolol Treatment in Schizophrenia
  679. Acute antipsychotic drug administration lowers body temperature in drug-free male schizophrenic patients
  680. Hemispheric function in disorganized type schizophrenia: performance on the Quality Extinction Test
  681. QT dispersion in the surface electrocardiogram in elderly patients with major depression
  682. Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients
  683. Beneficial effect of the addition of the 5-HT 2A/2C and α2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients
  684. Elevated circulatory level of GABAA – antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder
  685. Evidence for the involvement of the hippocampus in the pathophysiology of schizophrenia
  686. Myotoxicity and Neurotoxicity during Clozapine Treatment
  687. Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome
  688. Treating Depression in Alzheimer's Disease: Integration of Differing Guidelines
  689. Dopamine D4 receptor gene polymorphism and personality traits in healthy volunteers
  690. Is Melatonin Treatment Effective for Tardive Dyskinesia?
  691. Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse
  692. Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow
  693. Heat Intolerance in Patients With Chronic Schizophrenia Maintained With Antipsychotic Drugs
  694. Homeostatic biophasal conscious regulation
  695. Human Figure Drawings in the Evaluation of Severe Adolescent Suicidal Behavior
  696. The wired network as a learning paradigm for normal and abnormal brain neuronal communication
  697. Abnormal neuronal ionic flux activity: learning paradigms of schizophrenic thought disorders
  698. Effect of diazepam on the immune response of rats exposed to acute and chronic swim stress
  699. Unaltered α2-noradrenergic/imidazoline receptors in suicide victims: a postmortem brain autoradiographic analysis
  700. Actigraphic monitoring (actigraphy) of circadian locomotor activity in schizophrenic patients with acute neuroleptic-induced akathisia
  701. Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms
  702. Suppression of serum gonadal steroids in rats by chronic treatment with dopamine and serotonin reuptake inhibitors
  703. Haloperidol - induced neurotoxicity - possible implications for tardive dyskinesia
  704. Increased Risk for Dementia in Elderly Psychiatric Inpatients with Late-Onset Major Depression
  705. Search for association between suicide attempt and serotonergic polymorphisms
  706. Combined Electroconvulsive-Clozapine Therapy
  707. LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study
  708. Lifetime psychiatric comorbidity rate in Israeli non-help-seeking patients with combat-related post-traumatic stress disorder
  709. Neuroeyndocrinological Response to Standardized Mixed Meal in Female Anorectic Patients During Active and Refeeding Phases
  710. Obsessive-compulsive disorder in first episode and chronic schizophrenic patients
  711. Impact of Treatment for Childhood Obesity on Parental Risk Factors for Cardiovascular Disease
  712. Insulin-like-growth-factor-I (IGF-I) antagonizes apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture
  713. Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma☆☆☆★
  714. The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: An open label study
  715. Role of Nitric Oxide in the Enhancement of Pentylenetetrazole-Induced Seizures Caused by Shigella dysenteriae
  716. Partial eating disorders in newly drafted female recruits in Israel
  717. Elevated Cellular Immune Response to Human Heat-Shock Protein-60 in Schizophrenic Patients
  718. Lack of efficacy of the 5-HT3 receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia
  719. Ondansetron treatment in patients with Tourette??s syndrome
  720. Effects of psychotropic drugs on cell proliferation and differentiation
  721. Is there sexual dimorphism in obsessive-compulsive disorder?
  722. Platelet Peripheral-Type Benzodiazepine in Pregnancy and Lactation
  723. Orbitofrontal cortex dysfunction in obsessive–compulsive disorder?
  724. Orbitofrontal cortex dysfunction in obsessive-compulsive disorder?
  725. Decreased platelet peripheral-type benzodiazepine receptors in adolescent inpatients with repeated suicide attempts
  726. Serum cholesterol, suicidal tendencies, impulsivity, aggression, and depression in adolescent psychiatric inpatients
  727. Clozapine in elderly psychiatric patients: Tolerability, safety, and efficacy
  728. The effect of long-term antipsychotic treatment on the body weight of patients suffering from chronic schizophrenia: clozapine versus classical antipsychotic agents
  729. Lack of association between suicide attempt and a polymorphism at the dopamine receptor D4 locus
  730. Circulatory levels of catecholamines, serotonin and lipids in attention deficit hyperactivity diiorder
  731. Homicide by schizophrenic patients in Israel
  732. Low platelet-poor plasma concentrations of serotonin in patients with combat-related posttraumatic stress disorder
  733. 3H-Spiperone Binding to Lymphocytes in Neuroleptic-Naive-Schizophrenia and the Effect of Neuroleptic Treatment
  734. Biophysical shunt theory for neuropsychopathology: biphasal homeostatic dysregulation
  735. Biophysical shunt theory for neuropsychopathology: neuroimmunological causality for the suicide condition
  736. Biophysical shunt theory for neuropsychopathology: pentaphasic lipid-induced model for schizophrenia
  737. Fluvoxamine treatment of obsessivecompulsive symptoms in schizophrenic patients: an add-on open study
  738. The Impact of Clozapine Treatment on Serum Lipids in Chronic Schizophrenic Patients
  739. Involvement of Tumor Necrosis Factor Alpha and Interleukin-1β in Enhancement of Pentylenetetrazole-Induced Seizures Caused byShigella dysenteriae
  740. Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin
  741. Clinical characteristics of schizophrenia associated with velo-cardio-facial syndrome
  742. Intramuscular Flunitrazepam Versus Intramuscular Haloperidol in the Emergency Treatment of Aggressive Psychotic Behavior
  743. Use of Atypical Neuroleptics in Child and Adolescent Psychiatry
  744. Role of behaviour modification in the treatment of childhood obesity with the parents as the exclusive agents of change
  745. Elevated surum creatine kinase activity in adolescent psychiatric inpatients on admission
  746. Sleep Disturbances in Children with Attention-Deficit/Hyperactivity Disorder
  747. Antiproliferative and differentiating effects of benzodiazepine receptor ligands on B16 melanoma cells
  748. Reliability and validity of the Family Eating and Activity Habits Questionnaire
  749. Bone age in adolescents with schizophrenia and obsessive-compulsive disorder
  750. Interventional catheterization decreases plasma levels of atrial natriuretic peptide (ANP) in children with congenital heart defects
  751. The antinociceptive effect of moclobemide in mice is mediated by noradrenergic pathways
  752. The suicide brain: a review of postmortem receptor/transporter binding studies
  753. Zuclopenthixol, D1/D2 antagonist, for treatment of chronic aggressive schizophrenia and psychotic oligophrenic patients
  754. Linkage disequilibrium of common Gaucher disease mutations with a polymorphic site in thepyruvate kinase (PKLR) gene
  755. Elevated adhesiveness/aggregation of peripheral blood leukocytes in patients with major depression
  756. Intravenous Clomipramine for a Schizophrenic Patient With Obsessive-Compulsive Symptoms
  757. Low-Dose Mianserin in Treatment of Acute Neuroleptic-Induced Akathisia
  758. Parents as the exclusive agents of change in the treatment of childhood obesity
  759. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones
  760. Clinico-tremorgraphic features of neuroleptic-induced tremor
  761. Olanzapine treatment in patients with typical and atypical neuroleptic-associated agranulocytosis
  762. Psychiatric and polysomnographic evaluation of sleep disturbances
  763. Geriatric Depression Scale-Short Form–Validity and Reliability of the Hebrew Version
  764. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients
  765. Recurrence pattern of serum creatine phosphokinase levels in repeated acute psychosis
  766. Backpropagation and adaptive resonance theory in predicting suicidal risk
  767. Belief in Transmigration of the Soul and Psychopathology in Israeli Druze
  768. Combined clozapine-lithium treatment for schizophrenia and schizoaffective disorder
  769. Lateral preference in post-traumatic stress disorder
  770. Selective Serotonin Reuptake Inhibitor and Akathisia
  771. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine
  772. Velocardiofacial manifestations and microdeletions in schizophrenic inpatients
  773. Successful treatment of fluoxetine-indueed dystonia with low-dose mianserin
  774. Effect of neuroleptics on neuronal cell viability in primary mouse embryo brain cultures and a neuroblastoma cell-line, relevance to tardive dyskinesia
  775. Plasma neurosteroids (DHEA and DHEA-S) as markers of successful responsiveness to ECT (electroconvulsive therapy) in psychiatric patients
  776. Regulation of rat brain vesicular monoamine transporter (VMAT2) by chronic treatment with ovarian hormones
  777. The antinociceptive effect of moclobemide is mediated by noradrenergic pathways
  778. The interaction between the female hormonal system and the gene for the peripheral-type benzodiazepine receptor
  779. Reduction of Aggressiveness and Impulsiveness during Clozapine Treatment in Chronic Neuroleptic-Resistant Schizophrenic Patients
  780. Elevated levels of serum interleukin-1β in combat-related posttraumatic stress disorder
  781. Desmopressin (DDAVP) treatment in adult sleep-related enuresis
  782. Serotonergic agents in the treatment of acute neuroleptic-induced akathisia
  783. Partial Eating Disorders in a Community Sample of Female Adolescents
  784. Clozapine Treatment for Neuroleptic-Induced Tardive Dyskinesia, Parkinsonism, and Chronic Akathisia in Schizophrenic Patients
  785. THE ROLE OF INTELLIGENCE AND HYPERACTIVITY IN DIAGNOSIS OF ATTENTION DEFICIT DISORDER IN CHILDREN AND ADOLESCENTS
  786. Trihexyphenidyl treatment of clozapine-induced hypersalivation
  787. Neuroleptic malignant syndrome with gangliosidosis type II
  788. Evidence for an infectious etiology in autism
  789. Mianserin, a 5-HT2a/2c and α2 Antagonist, in the Treatment of Sexual Dysfunction Induced by Serotonin Reuptake Inhibitors
  790. Significant Inhibition of Spontaneous IgA Secretion by Selective Peripheral-Type Benzodiazepine Receptor Ligands
  791. An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia
  792. Opposite modulatory effects of ovarian hormones on rat brain dopamine and serotonin transporters
  793. Phase transitions and melting in Mars
  794. Role of lipid-induced changes in plasma membrane in the biophysical shunt theory of psychopathology
  795. Cerebral bioimpedance pattern as a function of psychiatric signs and symptoms
  796. Iron Treatment in Children with Attention Deficit Hyperactivity Disorder
  797. Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case series study
  798. Lithium and Male Sexual Function in Affective Patients
  799. Severe withdrawal akathisia following neuroleptic discontinuation successfully controlled by clozapine
  800. Hypothalamic-pituitary-ovarian axis and mood
  801. Serotonergic Drugs in Trichotillomania: Treatment Results in 12 Patients
  802. Low-Dose imipramine for thioridazineinduced male orgasmic disorder
  803. Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents
  804. Trihexyphenidyl (Artane) abuse in schizophrenic patients
  805. Differential effect of insulin-like growth factor-I and growth hormone on hypothalamic regulation of growth hormone secretion in the rat
  806. Fluvoxamine Treatment in Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenic Patients
  807. Obsessive-Compulsive Characteristics: From Symptoms to Syndrome
  808. Biophysical shunt theory for neuropsychopathology part II: Neuronal network miswiring
  809. Chronic GnRH agonist administration down-regulates platelet serotonin transporter in women undergoing assisted reproductive treatment
  810. HLA-B38 and clozapine agranulocytosis in Israeli Jewish schizophrenia patients
  811. TNFa microsatellite AC/GT repeat polymorphism and clozapine agranulocytosis in Israeli Jewish schizophrenia patients
  812. Depression in women treated with a gonadotropinreleasing hormone agonist
  813. Trihexyphenidyl as a possible therapeutic option in clozapine-induced nocturnal enuresis
  814. Combined clozapine-lithium treatment in schizophrenia and schizoaffective disorder
  815. Antinuclear autoantibodies in relation to bipolar affective disorder and lithium therapy
  816. Auditory Pseudohallucinations Induced by a Combination of Hearing Impairment and Environmental Stress
  817. Constraints on the structure and composition of Mars from thermal evolution models
  818. Functional hemisphere imbalance in patients with paranoid or disorganized schizophrenia
  819. Safety and effectiveness of combined ECT and clozapine in treatment-resistant mania
  820. Comparative models of Uranus and Neptune
  821. Suicide as a Work Accident
  822. Akathisia-like behavior following ECT, and its successful treatment with low-close mianserin
  823. Biophysical shunt theory for neuropsychopathology: Part I
  824. Lithium-induced akathisia responds to low-dose mianserin
  825. Fluvoxamine treatment of compulsivity, impulsivity, and aggression
  826. Antinuclear autoantibodies in chronic schizophrenia
  827. Cyproheptadine Treatment in Neuroleptic-Induced Akathisia
  828. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients
  829. Cyproheptadine Treatment of Sexual Dysfunction Induced by Serotonin Reuptake Inhibitors
  830. Effect of melatonin on active transport of serotonin into blood platelets
  831. Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient
  832. An Animal Model for the Study of Neurotoxicity of Bacterial Products and Application of the Model to Demonstrate that Shiga Toxin and Lipopolysaccharide Cooperate in Inducing Neurologic Disorders
  833. Constitutive heterochromatin of chromosome 1 and Duffy blood group alleles in schizophrenia
  834. Platelet peripheral-type benzodiazepine receptor in major depression
  835. Reduction in serotonin 5HT2 receptor binding on platelets of delinquent adolescents
  836. Caffeine withdrawal increases lithium blood levels
  837. Catatonia as an Unusual Presentation of Posttraumatic Stress Disorder
  838. Lack of association between cholesterol blood levels and platelet serotonin uptake
  839. The Belief in the Transmigration of Souls as a Presenting Symptom of Generalized Anxiety Disorder in a Military Setting
  840. Verapamil treatment in clozapine-induced sleep-related enuresis: a case report
  841. The psychobiology of obsessive-compulsive disorder
  842. Cortisol and prolactin response to fenfluramine in suicidal patients
  843. Verapamil Is Not an Antidepressant in Patients Resistant to Tricyclic Antidepressants
  844. Anticipatory consent for psychiatric treatment: A potential solution for an ethical problem
  845. Interactions between laudanosine, GABA, and opioid subtype receptors: implication for laudanosine seizure activity
  846. Cortisol and prolactin response to fenfluramine in suicidal patients
  847. Gonadotropin-releasing-hormone agonist induces depression in women
  848. Platelet serotonin transporter in drug-naive migrainous children and adolescents
  849. Tourette's disorder: Is there an association with the antiphospholipid syndrome?
  850. Fluvoxamine Open-Label Treatment of Adolescent Inpatients with Obsessive-Compulsive Disorder or Depression
  851. Brief Report
  852. Psychiatric Aspects of Hyperemesis gravidarum
  853. Clozapine Treatment in Very Early Onset Schizophrenia
  854. Internality and externality correlates of potential drivers among high school pupils in Holon (Israel)
  855. The Sociocultural Theory in the Development of Anorexia nervosa
  856. Erratum
  857. An Epidemiologic Study of Gilles de la Tourette's Syndrome in Israel
  858. Post-psychotic depression in schizophrenia
  859. POST MORTEM COMPUTERIZED TOMOGRAPHY IN TRAUMA VICTIMS. A NEW METHOD OF PM DIAGNOSIS
  860. Hippocampal γ-aminobutyric acid and benzodiazepine receptors after early phenobarbital exposure
  861. Repeated swim-stress reduces GABAA receptor α subunit mRNAs in the mouse hippocampus
  862. Reduced total complement haemolytic activity in schizophrenic patients
  863. Adrenal mitochondrial benzodiazepine receptors are sensitive to agents active at the dopamine receptor
  864. Long-Term Testosterone or Diethylstilbestrol Treatment Affects Gamma-Aminobutyric Acid and Central-Type Benzodiazepine Receptors but Not Peripheral-Type Benzodiazepine Receptors in the Female Rat Brain
  865. Ro 5-4864 and PK 11195, but Not Diazepam, Depress Cardiac Function in an Isolated Working Rat Heart Model
  866. Seizures induced by combined levomepromazine-fluvoxamine treatment
  867. Survey of Smoking Habits and Attitudes of Patients and Staff in Psychiatric Hospitals
  868. Clozapine—lithium combined treatment and agranulocytosis
  869. An Epidemiological Study of Obsessive-Compulsive Disorder and Related Disorders in Israeli Adolescents
  870. Elevated Plasma Immunoreactive β-Endorphin in Anorexia Nervosa
  871. Risk for Definite Neuroleptic Malignant Syndrome
  872. More Fluoxetine Experience
  873. ??-Tocopherol Treatment for Tardive Dyskinesia
  874. Decreased platelet imipramine binding in tourette syndrome children with obsessive-compulsive disorder
  875. Acute Transient Stress-Induced Hallucinations in Soldiers
  876. Neuroendocrine Response to Trihexyphenidyl in Depressed Patients
  877. Testosterone prevents castration-induced reduction in peripheral benzodiazepine receptors in Cowper's gland and adrenal
  878. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice
  879. Behavioral Profile and Social Competence in Temporal Lobe Epilepsy of Adolescence
  880. Haloperidol and lithium carbonate treatment did not influence serum immunoglobulin levels in schizophrenic and affective patients
  881. TRH stimulation test in obsessive-compulsive patients
  882. Peripheral benzodiazepine receptors on platelets in chronic and detoxified alcoholics☆
  883. Platelet peripheral benzodiazepine receptors in repeated stress
  884. Parental Anxiety Associated with a Child's Bronchial Asthma
  885. True Conversive Hallucinations
  886. Food deprivation modulates γ-aminobutyric acid receptors and peripheral benzodiazepine binding sites in rats
  887. Platelet benzodiazepine binding in Alzheimer's disease
  888. Identification and distribution of peripheral benzodiazepine binding sites in male rat genital tract
  889. Adrenalectomy prevents the stress-induced decrease in in vitro [3H]Ro15-1788 binding to GABAA benzodiazepine receptors in the mouse
  890. Long-term verapamil treatment increases [3H]imipramine binding in human platelets
  891. Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment
  892. Application of Basic Neuroscience to Child Psychiatry
  893. Introduction
  894. Biological Studies of Attention-Deficit Disorder
  895. Role of the GABA—Benzodiazepine Receptor Complex in Stress
  896. Effect of prenatal and neonatal chronic exposure to phenobarbital on central and peripheral benzodiazepine receptors
  897. Prolonged Fear of AIDS as an Early Symptom of Schizophrenia
  898. Chronic phenobarbital administration affects GABA and benzodiazepine receptors in the brain and periphery
  899. Stress-induced behavioral depression in the rat is associated with a decrease in GABA receptor-mediated chloride ion flux and brain benzodiazepine receptor occupancy
  900. LIGANDS SPECIFIC TO PERIPHERAL BENZODIAZEPINE RECEPTORS FOR TREATMENT OF PORPHYRIAS
  901. High Affinity Imipramine Binding and Serotonin Uptake in Human Platelets as a Peripheral Biological Marker in Neuropsychiatric Disorders
  902. Examination stress, platelet peripheral benzodiazepine binding sites, and plasma hormone levels
  903. Primary Hyperparathyroidism, Psychiatric Manifestations, Diagnosis and Management
  904. Suicide by Related Kidney Donors following the Recipients’ Death
  905. Tricyclic antidepressants and calcium channel blockers: interactions at the (−)-desmethoxyverapamil binding site and the serotonin transporter
  906. Vitamin B12and folic acid serum levels in obsessive compulsive disorder
  907. Plasma Cortisol, Prolactin, Growth Hormone, and Immunoreactive β-Endorphin Response to Fenfluramine Challenge in Depressed Patients
  908. The Sigma Receptor
  909. Imipramine binding to platelets of children with attention deficit disorder with hyperactivity
  910. Up-regulatory effect of triphasic oral contraceptive on platelet 3H-imipramine binding sites
  911. Clomipramine-Induced Urinary Dysfunction in an Obsessive-Compulsive Adolescent
  912. Serotonin 5-HT2 receptor binding on blood platelets - a peripheral marker for depression?
  913. Carbamazepine up-regulates the binding of [3H]PK 11195 to platelets of epileptic patients
  914. The effect of acute and repeated electroconvulsive treatment on plasma β-endorphin, growth hormone, prolactin and cortisol secretion in depressed patients
  915. Ontogenetic development of peripheral benzodiazepine binding sites in rat brain, heart and lung
  916. Regulation of central and peripheral benzodiazepine receptors in progesterone-treated rats
  917. Upregulation of imipramine binding and serotonin uptake by estradiol in female rat brain
  918. A successful electroconvulsive treatment of neuroleptic malignant syndrome
  919. Platelet [3H]imipramine binding in autism and schizophrenia
  920. Neuroleptic Malignant Syndrome
  921. Modulation of peripheral benzodiazepine binding sites following chronic estradiol treatment
  922. High-affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients
  923. Decreased peripheral benzodiazepine binding sites in platelets of neuroleptic-treated schizophrenics
  924. Sulpiride-induced hyperprolactinemia and impotence in male psychiatric outpatients
  925. Behavior Therapy, Pimozide Treatment and Prolactin Secretion in Anorexia Nervosa
  926. Decreased high affinity 3H-imipramine binding in platelets of enuretic children and adolescents
  927. Combination of Neuroleptic and Stimulant Treatment in Attention Deficit Disorder with Hyperactivity
  928. High dose diazepam treatment and its effect on prolactin secretion in adolescent schizophrenic patients
  929. Humoral-endorphin blood levels in autistic, schizophrenic and healthy subjects
  930. Basal Plasma HGH and Cortisol Levels and the Effect of Clonidine Administration in Female Migrainous Patients
  931. Dr. Weizman and Associates Reply
  932. The Correlation of Increased Serum Prolactin Levels with Decreased Sexual Desire and Activity in Elderly Men
  933. Sexual Dysfunction Associated with Hyperprolactinemia in Males and Females Undergoing Hemodialysis
  934. Abnormal growth hormone response to TRH in chronic adolescent schizophrenic patients
  935. Abnormal immune response to brain tissue antigen in the syndrome of autism
  936. Hyperprolactinemia: A Possible Cause of Sexual Impotence in Male Patients Undergoing Chronic Hemodialysis
  937. Hypercalcaemia-Induced Psychopathology in Malignant Diseases
  938. Neurogenetics of Anxiety Disorders